Skip to NavigationSkip to content


Top Ten most popular articles on this week!

The appointment of GSK veteran Arnaud Breabout to the position of Senior Vice President and CFO of Mundipharma took the top spot this week. Meanwhile MHRA chief Dr Ian Hudson announced he was stepping down.

Equally as Brexit inched ever closer it was revealed that use of antidepressant had gone up in the month following the referendum. At the same time, the ABPI responded to Theresa May’s new deal.

MHRA Chief to step down in 2019

The Medicines and Healthcare products Regulatory Agency (MHRA), the regulator responsible for the efficacy and safety of medicines in the UK, has announced that its Chief Executive is to step down from the role in September next year.

Dr Ian Hudson joined the then-Medicines Control Agency in 2001 as Licensing Director before stepping up to the role of CEO in 2013, his time with the organisation totalling 17 years.

Top Ten most popular articles on this week!

The Samsung scandal played a prominent role in this weeks’ top ten after the South Korean firm was delisted from the South Korean stock exchange over accounting violations. Equally Brexit chaos was central to this weeks’ news after a deal was revealed by Theresa May. The ongoing disruption has seen the resignation of a number of prominent players as backbench Brexiteer Jacob Rees Mogg called for a vote of no-confidence in Theresa May.

Phamaceutical trade lobby responds to Brexit deal

The Association of the British Pharmaceutical Industry (ABPI) has responded to Theresa May’s Brexit deal, after the government announced a 585 page draft withdrawal agreement has been agreed to by both the United Kingdom and the European Union.

However both the British and EU parliaments will now have to ratify the agreement. The news has already led to the resignation of Brexit Secretary Dominic Raab and Secretary of State for work and pensions, Esther McVey.

No-deal Brexit preparations are a waste of time and money, according to Welsh industry representatives

The UK government’s request that pharmaceutical companies stockpile an additional six weeks’ worth of medicine, in preparation for a no-deal Brexit, is a waste of time and money, representatives for the Welsh pharmaceutical industry have said.

While ‘robust plans have’ been put into place, the millions spent on stockpiling medicines in preparation for the unlikely scenario of a no-deal Brexit could be better spent on developing new medicines.

The November 2018 issue of Pharmafocus is available to read online now!

As the US continues to battle the demons in its healthcare system, Donald Trump looks like he may finally make good on his numerous and repeated promises to bring down drug prices, as well as bring  tangible action to the ongoing opioid crisis.

Since announcing a state of emergency over the latter crisis last year, the President has not been seen to attempt to affect any change on the issue, but hopes are high with the recent signing of a bipartisan bill which includes 200 provisions to tackle it, including partnerships with JJ&J, Facebook, Amazon and Google.

Top Ten most popular articles on this week!

Winter is coming! And with it an assortment of promising and not so promising results from big pharma. While J&J offered hope with their HIV vaccine, Bristol-Myer’s Squibb amazed with outstanding results for their Opdivo and Yervoy combo.

Industry leaders warn public may have to stockpile medicines in case of no-deal Brexit

Martin Sawer, the executive director of the Healthcare Distribution Association (HDA) – formerly the British Association of Pharmaceutical Wholesalers (BAPW) – has told MPs that a no-deal Brexit would have a ‘catastrophic’ effect on the supply of medicines coming into the UK, as he suggested that members of the public may have to personally stockpile drugs.

Top Ten most popular articles on this week

Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with SQZ Biotech, MSD’s and Samsung Bioepis’ deal fell through. Meanwhile Pfizer announced a cull of 2% of its staff amid a widespread restructuring.

AstraZeneca halting UK investment due to Brexit uncertainty

The Anglo-Swedish pharma firm AstraZeneca has suspended investment into the United Kingdom, due to the uncertainty surrounding Brexit.

The firm’s non-executive chairman, Leif Johansson, shed light on the company’s decision, in an interview with French newspaper Le Monde.

“If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest,” the Swedish businessman said to Le Monde.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches